Modeling immunotherapy of the tumor - Immune interaction

Journal of Mathematical Biology

Volumn 37, Issue 3, 1998, Pages 235-252

  Kirschner, Denise ^a   Panetta, John Carl ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BEHREND COLLEGE   (United States)

Author keywords

Cytokine; Immunotherapy; Interleukin 2; Modeling; Ordinary differential equations; Tumor

Indexed keywords

INTERLEUKIN 2; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BIOLOGICAL MODEL; CELL COMMUNICATION; HUMAN; IMMUNOLOGY; KINETICS; LYMPHOKINE ACTIVATED KILLER CELL; MATHEMATICAL COMPUTING; NEOPLASM; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; CELL COMMUNICATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KINETICS; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, IMMUNOLOGICAL; NEOPLASMS; NUMERICAL ANALYSIS, COMPUTER-ASSISTED;

EID: 0032160863     PISSN: 03036812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002850050127     Document Type: Article

References (37)

1. J. A. Adam. Effects of vascularization on lymphocyte/tumor cell dynamics: Qualitative features. Mathl. Comput. Modelling, 23(6): 1-10, 1996
2. J. A. Adam and N. Bellomo. A survey of Models for Tumor-Immune System Dynamics. Birkhäuser, Boston, MA, 1996
3. N. Blumberg, C. Chuang-Stein and J. M. Heal. The relationship of blook transfustion, tumor staging, and cancer recurrence. Transfusion, 30(4): 291-294, 1990
4. Brendan D. Curti, Augusto C. Ochoa, Walter J. Urba, W. Gregory Alvord, William C. Kopp, Gerry Powers, Connie Hawk, Stephen P. Creekmore, Barry L. Gause, John E. Janik, Jon T. Holmlund, Peter Kremers, Robert G. Fenton, Langdon Miller, Mario Sznol, John W. Smith II, William H. Sharfman and Dan L. Longo. Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients. Journal of Immunotherapy, 19(4): 296-308, 1996
5. R. J. DeBoer, Pauline Hogeweg, Hub F. J. Dullens, Roel A. DeWeger and Willem DenOtter. Macrophage T Lymphocyte interactions in the anti-tumor immune response: A mathematical model. The Journal of Immunology, 134(4): 2748-2758, April 1985
6. Charles DeLisi and Aldo Rescigno. Immune surveillance and neoplasia - I: a minimal mathematical model. Bull. Math. Biol., 39: 201-221, 1977
7. E. Doedel. AUTO - continuation and bifurcation software for ordinary differential equations. doedel@cs.concordia.edu, 1981
8. G. Bard Ermentrout. XPPAUT3.0 - the differential equations tool. http://info.pitt.edu/ ∼phase/, 1997
9. Richard A. Gatti, William A. Robinson, Amos S. Deinard, Mark Nesbit, Jeffrey J. McCullough, Mark Ballow and Robert A. Good. Cyclic leukocytosis in chronic myelogenous leukemia: New perspectives on pahtogenesis and therapy. Bood, 41(6): 771-781, June 1973
10. B. L. Gause, M. Sznol, W. C. Kopp, J. E. Janik, J. W. Smith II, R. G. Steis, W. J. Urba, W. Sharfman, R. G. Fenton, S. P. Creekmore, J. Holmlund, K. C. Conlon, L. A. VanderMolen and D. L. Longo. Phase I study of subcutaneously administered interleuking-2 in combination with interferon alfa-2a in patients with advanced cancer. Journal of Clinical Oncology, 14(8): 2234-2241, August 1996
11. Isao Hara, H. Hotta, N. Sato, H. Eto, S. Arakawa and S. Kamidono. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2. Jpn. J. Cancer Res., 87: 724-729, 1996
12. Yoshihiko Hirao, Eigoro Okajima, Seiichiro Ozono, Shoji Samma, Kenji Sasaki, Tadashi Hiramatsu, Katsuhiro Babaya, Shuji Watanabe and Yoshio Maruyama. A prospective randomixed study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT. Cancer Chemother Pharmacol, 30: S26-S30, 1992
13. Madelyn Holzman, Jr. C. Eugene Carlton and Peter T. Scardino. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage c prostate cancer. The Journal of Urology, 146: 1578-1582, December 1991
14. Raymond Kaempfer, L. Gerez, H. Farbstein, L. Madar, O. Hirschman, R. Nussinovich and A. Shapiro. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. Journal of Clinical Oncology, 14(6): 1778-1786, June 1996
15. U. Keilholz, C. Scheibenbogen, E. Stoelben, H. D. Saeger and W. Hunstein. Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. European Journal of Cancer, 30A(7): 955-958, 1994
16. B. J. Kennedy. Cyclic leukocyte oscillations in chronic mylegenous leukemia during hydroxyrtea therapy. Bood, 35(6): 751-760, June 1970
17. John G. Krikorian, Carol S. Portlock, D. Paul Cooney and Saul A. Rosenberg. Spontaneous regression of non-hodgkin's lymphoma: A report of nine cases. Cancer, 46: 2093-2099, 1980
18. V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson. Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis. Bull. Math. Biol., 56(2): 295-321, 1994
19. R. E. Lee, M. T. Lotze, J. M. Skibber, E. Tucker, R. O. Bonow, F. P. Ognibene, J. A. Carrasquillo, J. H. Shelhamer, J. E. Parillo and S. A. Rosenberg. Cardiorespiratory effects of ummunoltherapy with interleukin-2. Journal of Clinical Oncology, 7(1): 7-20, Jan 1989
20. R. Lefever and W. Horsthemke. Bistability in fluctuating environments. implications in tumor immunology. Bull. Math. Biol., 41: 469-90, 1979
21. Rene Lefever and Thomas Erneaux. On the growth of cellular tissues under constant and fluctuating environmental conditions. pp. 287-305, 1983
22. P. Lissoni, S. Barni, G. Cattaneo, C. Archili, S. Crispino, G. Tancine, L. D'Angelo, S. Magni, and G. Fiorelli. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. International Journal of Biological Markers, 5(4): 195-197, Oct-Dec 1990
23. Angela J. Lumsden, James P. Codde, Peter H. Van Der Meide and Bruce N. Gray. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-γ. Antocancer Research, 16: 1145-1154, 1996
24. F. M. Marincola, D. E. White, A. P. Wise and S. A. Rosenberg. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. Journal of Clinical Oncology, 13(5): 1110-1122, 1996
25. B. C. Mehta and M. B. Agarwal. Cyclic oscillations in leukocyte count in chronic myeloid leukemia. Acta Haematologica, 63: 68-70, 1980.
26. D. W. Miles, L. C. Happerfield, L. G. Bobrow and R. D. Rubens. Adhesion molecule expression and leucocyte rafficking following immunotherapy with recombinant interleukin-2. Histopatholgy, 28(4): 301-308, Apr 1996
27. A. A. Morley, A. G. Baikie, and D. A. G. Galton. Cyclic leucocytosis as evidence for retention of normal homoeostatic control in chronic granulocytic leukaemia. The Lancet, 1320-1323, December 1967
28. F. K. Nani and M. N. Oǧuztöreli. Modelling and simulation of Rosenberg-type adoptive cellular immunotherapy. IMA Journal of Mathematics Applied in Medicine & Biology, 11: 107-147, 1994
29. Hannah Rabinowich, Michael Banks, Torten E. Reichert, Theodore F. Logan, John M. Kirkwood and Theresa L. Whiteside. Expression and activity of signaling molecules n T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clinical Cancer Research, 2: 1263-1274, 1996.
30. S. A. Rosenberg and M. T. Lotze. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annual Review of Immunology, 4: 681-709, 1986
31. S. A. Rosenberg, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn and D. E. White. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 271(12): 907-913, 1994
32. M. Rosenstein, S. E. Ettinghousen and S. A. Rosenberg. Extravasion of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. Journal of Immunology, 137(5): 1735-1742, Sep 1986
33. Douglas J. Schwartzentruber. In Vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy. Current Opinion in Oncology, 5: 1055-1058, 1993
34. Abdolkarim Sohrabi, John Sandoz, John S. Spratt and Hiram C. Polk. Recurrence of breast cancer: Obesity, tumor size, and axillary lymph node metastases. JAMA, 244(3): 264-265, July 1980
35. E. Tartour, J. Y. Blay, T. Dorval, B. Escudier, V. Mosseri, J. Y. Douillard, L. Deneux, I. Gorin, S. Negrier, C. Mathiot, P. Pouillart and W. H. Fridman. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a french multi-institutional study. Journal of Clinical Oncology, 14(5): 1697-1703, 1996
36. Hensin Tsao, A. Benedict Cosimi, and Arthur J. Sober. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 79(12): 2361-2370, 1997
37. Helen Vodopick, Elizabeth M. Rupp, C. Lowell Edwards, Francis A. Goswitz and John J. Beauchamp. Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. The New England Journal of Medicine, 286(6): 284-290, Feb 1972